Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Q4 2024 Earnings Call Transcript
Q4 2024 Earnings Call Transcript March 20, 2025 Monte Rosa Therapeutics, Inc. beats earnings expectations. Reported EPS is $0 ...
Kepler Capital Keeps Their Buy Rating on Novartis AG (NOVN)
In a report released on March 21, David Evans from Kepler Capital maintained a Buy rating on Novartis AG (NOVN – Research Report), with a ...
Morgan Stanley says Fabhalta’s label leaves opportunity for Apellis’ Empaveli
Morgan Stanley analyst Judah Frommer notes that Novartis (NVS) has received FDA approval for Fabhalta for C3G. The label comes with a few important restrictions/caveats that leave room for Apellis’s ...
Novartis21h
Career Search
Explore opportunities with Novartis and Sandoz below. For additional roles with Novartis Gene Therapies (formerly AveXis) visit the GTx Career Search.